When Heart Patients Can’t Wait: Urgent TAVR with Self-Expanding Vs. Balloon-Expandable Valves

Why It Matters

The findings guide clinicians on valve selection for high‑risk urgent TAVR, balancing immediate procedural success with long‑term outcomes, and highlight the need to address concomitant mitral disease.

Key Takeaways

• Study includes ~600 urgent/emergent TAVR cases (2012‑2024).
• Long‑term mortality similar for self‑expanding and balloon‑expandable valves.
• Balloon‑expandable valves showed higher technical and device success overall.
• No outcome advantage after excluding older‑generation valves.
• Pre‑procedure mitral regurgitation predicts poorer long‑term survival.

Pulse Analysis

Urgent and emergent TAVR procedures occupy a niche where time‑sensitive decision‑making can dictate patient survival. Unlike elective cases, these patients often present with decompensated heart failure, cardiogenic shock, or acute coronary syndromes, leaving little margin for extensive pre‑procedural testing. The rapid evolution of transcatheter heart valve technology—particularly the shift from first‑generation to contemporary devices—has expanded the therapeutic window, allowing operators to choose between self‑expanding and balloon‑expandable platforms based on anatomical fit, delivery system profile, and operator familiarity. Understanding how each valve performs under these pressured conditions is essential for hospitals aiming to optimize outcomes and resource utilization.

The multi‑center study spanning 12 years revealed that, while overall mortality was comparable between SEVs and BEVs, balloon‑expandable valves delivered higher technical and device success rates and reduced in‑hospital death rates in the full cohort. These early advantages likely stem from the more predictable deployment mechanics of BEVs, which can be crucial when patients cannot tolerate prolonged procedural times. However, when the analysis focused on patients receiving newer‑generation valves, the differences vanished, underscoring how iterative design improvements—such as lower profile delivery systems and enhanced sealing skirts—have narrowed the performance gap. For health systems, this suggests that investment in the latest valve iterations may be more impactful than platform selection alone.

A striking secondary finding was the independent prognostic weight of pre‑TAVR mitral regurgitation, linking it to higher long‑term mortality regardless of valve type. This highlights an emerging paradigm: addressing co‑existing valvular lesions, perhaps through staged transcatheter edge‑to‑edge repair or combined procedures, could improve survival and quality of life for this high‑risk cohort. As the market for transcatheter solutions expands, manufacturers and clinicians alike must consider integrated treatment pathways that account for multi‑valve disease, while ongoing registries will be vital to refine risk models and guide future guideline updates.